Drug intelligence / Profile preview

hydroxy[3-(6-methylpyridin-2-yl)propyl]formamide

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules

Overview

Hydroxy[3-(6-methylpyridin-2-YL)propyl]formamide is a synthetic small molecule inhibitor of peptide deformylase, an enzyme involved in the removal of formyl groups from nascent proteins in bacteria. By inhibiting peptide deformylase, this compound disrupts bacterial protein maturation and has been investigated as a potential antibacterial agent. It is considered experimental and has not been approved for clinical use. The compound is also known by code names such as SB-505684 and SB9[1][5][7].

Other names: N-hydroxy-N-[3-(6-methylpyridin-2-yl)propyl]formamideHYDROXY(3-(6-METHYLPYRIDIN-2-YL)PROPYL)FORMAMIDE

Targets

PDF (Peptide deformylase, mitochondrial)

Beyond the preview

Go deeper on hydroxy[3-(6-methylpyridin-2-yl)propyl]formamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydroxy[3-(6-methylpyridin-2-yl)propyl]formamide.

Explore the full profile